| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Schepens Eye Research Institute, Department of Ophthalmology, Harvard Medical School, Boston, MA 02114; and
Department of Microbiology, Boston University School of Medicine, Boston, MA 02118
It has been proposed that the constitutive expression of Fas ligand (FasL) in the eye maintains immune privilege, in part through inducing apoptosis of infiltrating Fas+ T cells. However, the role of FasL in immune privilege remains controversial due to studies that indicate FasL is both pro- and anti-inflammatory. To elucidate the mechanism(s) by which FasL regulates immune privilege, we used an ocular tumor model and examined the individual roles of the membrane-bound and soluble form of FasL in regulating ocular inflammation. Following injection into the privileged eye, tumors expressing only soluble FasL failed to trigger inflammation and grew progressively. By contrast, tumors expressing only membrane FasL 1) initiated vigorous neutrophil-mediated inflammation, 2) terminated immune privilege, and 3) were completely rejected. Moreover, the rejection coincided with activation of both innate and adaptive immunity. Interestingly, a higher threshold level of membrane FasL on tumors is required to initiate inflammation within the immune privileged eye, as compared with nonprivileged sites. The higher threshold is due to the suppressive microenvironment found within aqueous humor that blocks membrane FasL activation of neutrophils. However, aqueous humor is unable to completely block the proinflammatory effects of tumor cells that express high levels of membrane FasL. In conclusion, our data indicate that the function of FasL on intraocular tumors is determined by the microenvironment in conjunction with the form and level of FasL expressed.
This article has been cited by other articles:
|
|
 |
|
  M. S. Gregory, R. R. Saff, A. Marshak-Rothstein, and B. R. Ksander Control of Ocular Tumor Growth and Metastatic Spread by Soluble and Membrane Fas Ligand Cancer Res., December 15, 2007; 67(24): 11951 - 11958. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-C. Su, Y.-P. Lin, Y.-J. Cheng, J.-Y. Huang, W.-J. Chuang, Y.-S. Shan, and B.-C. Yang Phosphatidylinositol 3-Kinase/Akt Activation by Integrin-Tumor Matrix Interaction Suppresses Fas-Mediated Apoptosis in T Cells J. Immunol., October 1, 2007; 179(7): 4589 - 4597. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Lin, E. Carlson, E. Diaconu, and E. Pearlman CXCL1/KC and CXCL5/LIX are selectively produced by corneal fibroblasts and mediate neutrophil infiltration to the corneal stroma in LPS keratitis J. Leukoc. Biol., March 1, 2007; 81(3): 786 - 792. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Chen, S. Liu, D. Park, Y. Kang, and G. Zheng Depleting Intratumoral CD4+CD25+ Regulatory T Cells via FasL Protein Transfer Enhances the Therapeutic Efficacy of Adoptive T Cell Transfer Cancer Res., February 1, 2007; 67(3): 1291 - 1298. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. C. McKenna and J. A. Kapp Accumulation of Immunosuppressive CD11b+ Myeloid Cells Correlates with the Failure to Prevent Tumor Growth in the Anterior Chamber of the Eye J. Immunol., August 1, 2006; 177(3): 1599 - 1608. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Guo, M. Zhang, H. Tang, and X. Cao Fas signal links innate and adaptive immunity by promoting dendritic-cell secretion of CC and CXC chemokines Blood, September 15, 2005; 106(6): 2033 - 2041. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Engelbert and M. S. Gilmore Fas Ligand but Not Complement Is Critical for Control of Experimental Staphylococcus aureus Endophthalmitis Invest. Ophthalmol. Vis. Sci., July 1, 2005; 46(7): 2479 - 2486. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Gregory, S. Koh, E. Huang, R. R. Saff, A. Marshak-Rothstein, S. Mukai, and B. R. Ksander A Novel Treatment for Ocular Tumors Using Membrane FasL Vesicles to Activate Innate Immunity and Terminate Immune Privilege Invest. Ophthalmol. Vis. Sci., July 1, 2005; 46(7): 2495 - 2502. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Vij, L. Roberts, S. Joyce, and S. Chakravarti Lumican Regulates Corneal Inflammatory Responses by Modulating Fas-Fas Ligand Signaling Invest. Ophthalmol. Vis. Sci., January 1, 2005; 46(1): 88 - 95. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Frangsmyr, V. Baranov, O. Nagaeva, U. Stendahl, L. Kjellberg, and L. Mincheva-Nilsson Cytoplasmic microvesicular form of Fas ligand in human early placenta: switching the tissue immune privilege hypothesis from cellular to vesicular level Mol. Hum. Reprod., January 1, 2005; 11(1): 35 - 41. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Gillette-Ferguson, A. G. Hise, H. F. McGarry, J. Turner, A. Esposito, Y. Sun, E. Diaconu, M. J. Taylor, and E. Pearlman Wolbachia-Induced Neutrophil Activation in a Mouse Model of Ocular Onchocerciasis (River Blindness) Infect. Immun., October 1, 2004; 72(10): 5687 - 5692. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Scholz, A. Simon, M. Berg, A. M. Schuller, M. Hacibayramoglu, S. Margraf, A. Theisen, J. Windolf, G. Wimmer-Greinecker, and A. Moritz In vivo inhibition of neutrophil activity by a FAS (CD95) stimulating module: Arterial in-line application in a porcine cardiac surgery model J. Thorac. Cardiovasc. Surg., June 1, 2004; 127(6): 1735 - 1742. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. M. Abrahams, S. L. Straszewski-Chavez, S. Guller, and G. Mor First trimester trophoblast cells secrete Fas ligand which induces immune cell apoptosis Mol. Hum. Reprod., January 1, 2004; 10(1): 55 - 63. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. M. Abrahams, S. L. Straszewski, M. Kamsteeg, B. Hanczaruk, P. E. Schwartz, T. J. Rutherford, and G. Mor Epithelial Ovarian Cancer Cells Secrete Functional Fas Ligand Cancer Res., September 1, 2003; 63(17): 5573 - 5581. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. A. Kayisli, B. Selam, O. Guzeloglu-Kayisli, R. Demir, and A. Arici Human Chorionic Gonadotropin Contributes to Maternal Immunotolerance and Endometrial Apoptosis by Regulating Fas-Fas Ligand System J. Immunol., September 1, 2003; 171(5): 2305 - 2313. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-L. Chen, S.-H. Chen, J.-Y. Wang, and B.-C. Yang Fas Ligand on Tumor Cells Mediates Inactivation of Neutrophils J. Immunol., August 1, 2003; 171(3): 1183 - 1191. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Hoves, S. W. Krause, D. Halbritter, H.-G. Zhang, J. D. Mountz, J. Scholmerich, and M. Fleck Mature But Not Immature Fas Ligand (CD95L)-Transduced Human Monocyte-Derived Dendritic Cells Are Protected from Fas-Mediated Apoptosis and Can Be Used as Killer APC J. Immunol., June 1, 2003; 170(11): 5406 - 5413. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-S. Mo, M. G. Anderson, M. Gregory, R. S. Smith, O. V. Savinova, D. V. Serreze, B. R. Ksander, J. W. Streilein, and S. W.M. John By Altering Ocular Immune Privilege, Bone Marrow-derived Cells Pathogenically Contribute to DBA/2J Pigmentary Glaucoma J. Exp. Med., May 19, 2003; 197(10): 1335 - 1344. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Yang, S. P. Jones, T. Suhara, J. J. M. Greer, P. D. Ware, N. P. Nguyen, H. Perlman, D. P. Nelson, D. J. Lefer, and K. Walsh Endothelial Cell Overexpression of Fas Ligand Attenuates Ischemia-Reperfusion Injury in the Heart J. Biol. Chem., April 18, 2003; 278(17): 15185 - 15191. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
